An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint

Gene Therapy

Volumn 11, Issue 7, 2004, Pages 581-590

  van de Loo, F A J ^a   de Hooge, A S K ^a   Smeets, R L ^a   Bakker, A C ^a   Bennink, M B ^a   Arntz, O J ^a   Joosten, L A B ^a   van Beuningen, H M ^a   van der Kraan, P K ^a   Varley, A W ^b   van den Berg, W B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Molecular Host Defense Laboratory   (United States)

Author keywords

Adenovirus; Arthritis; Gene knockout; Inducible promoter; Mice

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENT COMPONENT C3; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LUCIFERASE; TRANSACTIVATOR PROTEIN; ZYMOSAN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CELL LINE; CONTROLLED STUDY; CYTOMEGALOVIRUS; FIBROBLAST; GENE CONSTRUCT; GENE EXPRESSION; GENE SILENCING; HYBRID; IN VIVO STUDY; KNEE; KNOCKOUT GENE; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RHEUMATOID ARTHRITIS; STREPTOCOCCUS; SYNOVIUM; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, BACTERIAL; ARTHRITIS, INFECTIOUS; CYTOKINES; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROMOTER REGIONS (GENETICS); STREPTOCOCCUS; TRANSDUCTION, GENETIC; ZYMOSAN;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS;

EID: 11144353653     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302182     Document Type: Review

References (66)

1. Mattsson R et al. Maintained pregnancy levels of oestrogen afford complete protection from post-partum exacerbation of collagen-induced arthritis. Clin Exp Immunol 1991; 85: 41-47.
2. Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol 1983; 12: 69-72.
3. Bischof RJ, Zafiropoulos D, Hamilton JA, Campbell IK. Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: Evidence of macrophage infiltration and local proliferation. Clin Exp Immunol 2000; 119: 361-367.
4. Lens JW et al. Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: Effects of pre-treatment with cobra venom factor and anti-lymphocyte serum. Clin Exp Immunol 1984; 57: 520-528.
5. van de Loo AA, Arntz OJ, van den Berg WB. Flare-up of experimental arthritis in mice with murine recombinant IL-1. Clin Exp Immunol 1992; 87: 196-202.
6. van Lent PL et al. Phagocytic synovial lining cells regulate acute and chronic joint inflammation after antigenic exacerbation of smouldering experimental murine arthritis. J Rheumatol 1998; 25: 1135-1145.
7. van de Loo AA et al. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995; 146: 239-249.
8. van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin N Am 2002; 28: 127-149.
9. Baragi VM. MFG-IRAP University of Pittsburgh. Curr Opin Invest Drugs 2000; 1: 194-198.
10. Evans CH et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-1280.
11. Roth S et al. [Anti-TNF alpha monoclonal antibodies (infliximab) and tuberculosis: Apropos of 3 cases]. Rev Med Interne 2002; 23: 312-316.
12. Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 2002; 31: 44-45.
13. Nunez MO et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001; 96: 1665-1666.
14. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 1885-1888.
15. Imhof MO, Chatellard P, Mermod N. Comparative study and identification of potent eukaryotic transcriptional repressors in gene switch systems. J Biotechnol 2002; 97: 275-285.
16. Varley AW, Geiszler SM, Gaynor RB, Munford RS. A two-component expression system that responds to inflammatory stimuli in vivo. Nat Biotechnol 1997; 15: 1002-1006.
17. Bakker AC et al. C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene. Arthritis Rheum 2002; 46: 1661-1670.
18. Miagkov AV, Varley AW, Munford RS, Makarov SS. Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints. J Clin Invest 2002; 109: 1223-1229.
19. van de Loo FA et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-172.
20. Kuiper S et al. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998; 10: 690-702.
21. Kim YM, Son K. A nitric oxide production bioassay for interferon-gamma. J Immunol Methods 1996; 198: 203-209.
22. Kline JN et al. Synergistic activation of the human cytomegalovirus major immediate early promoter by prostaglandin E2 and cytokines. Exp Lung Res 1998; 24: 3-14.
23. Stein J et al. Tumor necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/ promoter in immature monocytic cells. J Gen Virol 1993; 74: 2333-2338.
24. Ritter T et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 2000; 12: 1163-1170.
25. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFkappaB. J Virol 1998; 72: 180-190.
26. Prosch S et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. Virology 1995; 208: 197-206.
27. Cheeran MC, Hu S, Gekker G, Lokensgard JR. Decreased cytomegalovirus expression following proinflammatory cytokine treatment in primary human astrocytes. J Immunol 2000; 164: 926-933.
28. Qin L et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
29. Razin A. CpG methylation, chromatin structure and gene silencing - a three-way connection. EMBO J 1998; 17: 4905-4908.
30. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol 2002; 22: 3157-3173.
31. Prosch S et al. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 1996; 377: 195-201.
32. Benihoud K et al. Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha. J Virol 1998; 72: 9514-9525.
33. Zhang HG et al. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 1998; 9: 1875-1884.
34. Elkon KB et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 1997; 94: 9814-9819.
35. Peng Y et al. Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J Virol 1999; 73: 5098-5109.
36. Pan RY et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-297.
37. Pan RY et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol 1999; 73: 3410-3417.
38. Teschendorf C, Warrington Jr KH, Siemann DW, Muzyczka N. Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res 2002; 22: 3325-3330.
39. Varley AW, Munford RS. Physiologically responsive gene therapy. Mol Med Today 1998; 4: 445-451.
40. Bednarik DP, Cook JA, Pitha PM. Inactivation of the HIV LTR by DNA CpG methylation: Evidence for a role in latency. EMBO J 1990; 9: 1157-1164.
41. Kopf M et al. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med 1998; 188: 1895-1906.
42. Deng C et al. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 2002; 169: 1077-1083.
43. Kawamura N, Singer L, Wetsel RA, Colten HR. Cis-and transacting elements required for constitutive and cytokine-regulated expression of the mouse complement C3 gene. Biochem J 1992; 283 (Part 3): 705-712.
44. Wilson DR et al. A 58-base-pair region of the human C3 gene confers synergistic inducibility by interleukin-1 and interleukin-6. Mol Cell Biol 1990; 10: 6181-6191.
45. Buonaguro L et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992; 66: 7159-7167.
46. Scala G et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994; 179: 961-971.
47. Bakker AC et al. Prevention of murine collagen-induced arthritis in the knee and the ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893-900.
48. Lechman ER et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 1999; 163: 2202-2208.
49. Boyle DL et al. Intra-articular IL-4 gene therapy in arthritis: Anti-inflammatory effect and enhanced Th2 activity. Gene Therapy 1999; 6: 1911-1918.
50. Kim SH et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells geneticaly modified to express IL-4. J Immunol 2001; 166: 3499-3505.
51. Kim SH et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002; 6: 591-600.
52. Chan JM et al. Intraarticular gene transfer of TNFR:FC suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002; 6: 727-736.
53. Underhill DM, Ozinsky A. Toll-like receptors: Key mediators of microbe detection. Curr Opin Immunol 2002; 14: 103-110.
54. Horai R et al. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998; 187: 1463-1475.
55. Kopf M et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
56. Kinoshita S, Akira S, Kishimoto T. A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc Natl Acad Sci USA 1992; 89: 1473-1476.
57. Abe M et al. Regulation of interleukin (IL)-1beta gene transcription induced by IL-1beta in rheumatoid synovial fibroblast-like cells, E11, transformed with simian virus 40 large T antigen. J Rheumatol 1997; 24: 420-429.
58. Chartier C et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810.
59. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy J Virol 1996; 70: 7498-7509.
60. Fallaux FJ et al. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
61. Erbacher P. Methods for adenovirus-mediated gene transfer to airway epithelium. In: Robbins PD (ed). Methods in Molecular Medicine, Gene Therapy Protocols. Humana press Inc.: Totowa, NJ, 1997, pp 169-184.
62. van Beuningen HM et al. Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage. Osteoarthritis Cartilage 2002; 10: 977-986.
63. Ebbinghaus C et al. Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter. J Virol 2001; 75: 480-489.
64. van den Broek MF, van den Berg WB, van de Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988; 133: 139-149.
65. Butel JS, TAlas M, Ugur J, Melnick JL. Demonstration of infectious DNA in transformed cells. III. Correlation of detection of infectious DNA-protein complexes with persistence of virus in simian adenovirus SA7-induced tumor cells. Intervirology 1975; 5: 43-56.
66. Morris DJ, Cooper RJ, Barr T, Bailey AS. Polymerase chain reaction for rapid diagnosis of respiratory adenovirus infection. J Infect 1996; 32: 113-117.